Latest News

Novartis launches Prevacid

Covidien Introduces First FDA-Approved Spine Sealant

The European Commission grants Orphan Drug designation for NGR-hTNF in the treatment of hepatocellular carcinoma

Kensey Nash Receives FDA 510(k) Clearance for Porcine Dermis Biologic Product

Pandemic 2009 Influenza Update: US FDA approves GSK's pandemic H1N1 vaccine

IRONWOOD AND ASTELLAS ANNOUNCE JAPAN LICENSING AGREEMENT FOR LINACLOTIDE

Merit Medical Announces 510(K) Clearance for the Merit Laureate(TM) Hydrophilic Guide Wire

Lonza successfully develops a manufacturing process for ArzerraTM (ofatumumab), a new biopharmaceutical from GSK and Genmab

Teva Receives Favorable Court Decision Regarding Generic Prevacid

Teva Receives Final Approval For Generic Prevacid

More news... | RSS Feed...

Most Viewed

FDA GRANTS ORPHAN DRUG DESIGNATION FOR TNFERADE(TM)

Shire Targets Fourth Quarter Filing of BLA for REPLAGAL

Cephalon Notified of Generic Filing for Armodafinil Tablets

ONCOLYS BIOPHARMA SIGN STRATEGIC ALLIANCE AND LICENSE AGREEMENT WITH ASTELLAS PHARMA TO DEVELOP AND COMMERCIALIZE YM753 HDAC INHIBITOR DRUG

The European Commission grants Orphan Drug designation for NGR-hTNF in the treatment of hepatocellular carcinoma

Acorda Therapeutics Announces Extension of Fampridine-SR PDUFA Goal Date to January 22, 2010

Tarix Pharmaceuticals receives FDA approval for Phase 2 study to mitigate chemotherapy-induced thrombocytopenia

Tarix Pharmaceuticals receives IND to treat HIV patients with persistently low CD4 counts

Antigenics Announces a Negative Vote From the CHMP on Oncophage

Lonza successfully develops a manufacturing process for ArzerraTM (ofatumumab), a new biopharmaceutical from GSK and Genmab

Therapeutic Target

Cardiovascular

Dermatology

Endocrine and Metabolic

Gastroenterology

Genitourinary

Hematology

Immunology and Allergy

Infection

Musculoskeletal

Neurology

Obstetrics and Gynecology

Oncology

Ophthalmology

Psychiatry

Pulmonary

Categories

Deals and Alliances

Development

Financial Results

Financings

Intellectual Property

Regulatory

Press releases

Deals review

Headlines

PR Newswire